Literature DB >> 2413297

Plasma protein binding and erythrocyte partitioning of nicardipine in vitro.

S Urien, E Albengres, A Comte, J R Kiechel, J P Tillement.   

Abstract

Using isotope techniques, equilibrium dialysis, and incubation experiments, we characterized the binding of nicardipine to isolated plasma proteins, human serum, blood cells, and platelets. Nicardipine was mainly bound to lipoproteins, orosomucoïd, albumin, and erythrocytes in human blood. Nicardipine, pindolol, and imipramine were found to share the same site on orosomucoïd. The determinants of nicardipine binding to lipoproteins were triglycerides, phospholipids, and cholesterol ester. Nicardipine partitioned into erythrocytes, showing a constant ratio of distribution between the intra- and extracellular compartments. Nicardipine partitioned less to erythrocytes when increasing amounts of binding plasma proteins were present in the extracellular compartment. In human blood, 12 to 18% of total nicardipine was present in erythrocytes. The overall binding of nicardipine in serum varied from 98 to 99.5% and correlated with serum orosomucoïd and serum lipid concentrations.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2413297     DOI: 10.1097/00005344-198509000-00012

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

1.  Simultaneous study of the pharmacokinetics of intravenous and oral nicardipine using a stable isotope.

Authors:  M Guerret; G Cheymol; M Hubert; C Julien-Larose; D Lavene
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

Review 3.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

4.  The plasma protein binding of basic drugs.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

5.  Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery.

Authors:  P Jolliet; N Simon; F Brée; S Urien; A Pagliara; P A Carrupt; B Testa; J P Tillement
Journal:  Pharm Res       Date:  1997-05       Impact factor: 4.200

Review 6.  Pharmacokinetics of calcium antagonists under development.

Authors:  D R Abernethy; J B Schwartz
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

Review 7.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

Review 8.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

9.  Intravenous nicardipine does not alter hepatic blood flow after orthotopic liver transplant.

Authors:  M Raucoules-Aimé; M Drici; B Goubaux; Y Labib; C Ichai; J Gugenheim; D Grimaud
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

10.  Cimetidine does not increase alpha 1-acid glycoprotein serum concentrations.

Authors:  R C Parish; V P Gotz; J L Mehta
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.